RedHill Biopharma Ltd. American
RedHill Biopharma Ltd. American Depositary Shares represent ownership interests in RedHill Biopharma Ltd., a specialty biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal diseases, infectious diseases, and oncology. The company’s current portfolio includes marketed products and clinical-stage programs centered on oral therapies and targeted treatments for adult patients and other specialized medical needs. RedHill Biopharma operates across commercial operations and research and development, combining product sales activities with ongoing clinical advancement. Its business is aimed at addressing areas where treatment options can be limited, making it a participant in the broader specialty pharmaceuticals market. RedHill Biopharma Ltd. is headquartered in Tel Aviv, Israel, and its American Depositary Shares provide U.S. investors with a way to access the company through a depositary share structure.
$0.48
-$0.02 (-3.81%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-2765.38% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$286K
Net Income (TTM)
-$429K
▲ +94.8% YoY
Op. Margin
-2765.38%
ROIC
-219.46%
▲ +64.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -3.0% YoY
Op. Cash Flow (TTM)
-$10M
▼ -3.0% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$4M
3Y CAGR: -83.3%
Continue Research
Is RedHill Biopharma Ltd. American (RDHL) overvalued?
RedHill Biopharma Ltd. American (RDHL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, RedHill Biopharma Ltd. American scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is RedHill Biopharma Ltd. American a high-quality business?+
RedHill Biopharma Ltd. American scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -2,765.4% operating margin and a -219.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is RedHill Biopharma Ltd. American a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh RDHL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.